Project Grant R21CA299390
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $432K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- Federal Grant Award Summary Albert Einstein College of Medicine received a $687,291 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award funds fundamental research investigating how cancer driver mutations—specifically MLL3 (also known as KMT2C) loss combined with PI3KCA activation and P53 inactivation—promote immune suppression in breast cancer through regulatory T (Treg) cell...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, through April 30, 2031. The award supports research and development of MTAP (methylthioadenosine phosphorylase) transition state analog inhibitors as a novel synthetic-lethal therapeutic approach for cancer treatment. The research focuses on developing highly specific,...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $561,407 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded on June 18, 2026, with a completion date of May 31, 2031. This grant funds fundamental research into the causal mechanisms driving germline predisposition to myeloproliferative neoplasms (MPNs), specifically investigating how common genetic variants identified through genome-wide association...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $168,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026 through March 31, 2028. The award supports research to investigate dormancy mechanisms in pancreatic ductal adenocarcinoma (PDAC) and identify therapeutic targets to improve patient survival outcomes. The project focuses on understanding how disseminated tumor cells...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Albert Einstein College of Medicine a $680,121 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026, through March 31, 2031, to investigate immunoevasion mechanisms in basal-like breast cancer (BLBC) precancer stem cells. The research focuses on understanding how precancerous stem-like cells (pre-CSCs) escape immune surveillance through the SOX9-B7X immune checkpoint pathway, with...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG). The award, effective April 1, 2026 through March 31, 2028, supports the development and characterization of novel humanized TROP2 mouse...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Albany Medical College a $648,579 Project Grant effective June 1, 2026, through the Cancer Detection and Diagnosis Research program (CFDA 93.394) to investigate the mechanistic relationship between tumor biomechanics and monoclonal antibody (MAB) therapeutic efficacy in HER2-positive breast cancer. The project, which extends through May 31, 2031, will generate spatially resolved datasets examining how tumor...
- Federal Grant Award Summary New York University School of Medicine received a $585,482 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) awarded June 1, 2026, with completion targeted for May 31, 2031. This research grant funds fundamental investigation into the molecular mechanisms of breast cancer metastasis, specifically examining the role of the translation factor DAP5 (Death-Associated Protein 5) in selective messenger ribonucleic...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded The Trustees of Columbia University in the City of New York $594,297 on June 18, 2026, for a project entitled "Elasticity Imaging of Breast Cancer During Treatment." The five-year project, which runs through May 31, 2031, will develop and validate two noninvasive theranostic methodologies for characterizing and treating female...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Johns Hopkins University a $144,193 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective September 4, 2025 through August 31, 2030. This award provides protected salary support for Dr. Preethi Korangath to serve as a Laboratory Research Specialist in Dr. Robert Ivkov's laboratory, where she will facilitate the completion of Research Project Grants (R01) by leveraging her expertise...